Literature DB >> 10049833

Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b.

J Wimmer1, K Fujinaga, R Taube, T P Cujec, Y Zhu, J Peng, D H Price, B M Peterlin.   

Abstract

The transcriptional transactivator (Tat) from the human immunodeficiency virus (HIV) does not function efficiently in Chinese hamster ovary (CHO) cells. Only somatic cell hybrids between CHO and human cells and CHO cells containing human chromosome 12 (CHO12) support high levels of Tat transactivation. This restriction was mapped to interactions between Tat and TAR. Recently, human cyclin T1 was found to increase the binding of Tat to TAR and levels of Tat transactivation in rodent cells. By combining individually with CDK9, cyclin T1 or related cyclins T2a and T2b form distinct positive transcription elongation factor b (P-TEFb) complexes. In this report, we found that of these three cyclins, only cyclin T1 is encoded on human chromosome 12 and is responsible for its effects in CHO cells. Moreover, only human cyclin T1, not mouse cyclin T1 or human cyclins T2a or T2b, supported interactions between Tat and TAR in vitro. Finally, after introducing appropriate receptors and human cyclin T1 into CHO cells, they became permissive for infection by and replication of HIV. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10049833     DOI: 10.1006/viro.1998.9589

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  28 in total

Review 1.  P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II.

Authors:  D H Price
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

2.  TAR RNA loop: a scaffold for the assembly of a regulatory switch in HIV replication.

Authors:  Sara Richter; Yueh-Hsin Ping; Tariq M Rana
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-04       Impact factor: 11.205

3.  Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells.

Authors:  P D Bieniasz; B R Cullen
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.

Authors:  Kieran Seay; Nazanin Khajoueinejad; Jian Hua Zheng; Patrick Kiser; Christina Ochsenbauer; John C Kappes; Betsy Herold; Harris Goldstein
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

Review 5.  Structural determinants and mechanism of HIV-1 genome packaging.

Authors:  Kun Lu; Xiao Heng; Michael F Summers
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

6.  Cyclin T1 expression is mediated by a complex and constitutively active promoter and does not limit human immunodeficiency virus type 1 Tat function in unstimulated primary lymphocytes.

Authors:  Juan Martin-Serrano; Kelvin Li; Paul D Bieniasz
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

7.  CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA.

Authors:  M E Garber; T P Mayall; E M Suess; J Meisenhelder; N E Thompson; K A Jones
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

8.  9-Aminoacridine inhibition of HIV-1 Tat dependent transcription.

Authors:  Irene Guendel; Lawrence Carpio; Rebecca Easley; Rachel Van Duyne; William Coley; Emmanuel Agbottah; Cynthia Dowd; Fatah Kashanchi; Kylene Kehn-Hall
Journal:  Virol J       Date:  2009-07-24       Impact factor: 4.099

9.  Crystal structure of HIV-1 Tat complexed with human P-TEFb.

Authors:  Tahir H Tahirov; Nigar D Babayeva; Katayoun Varzavand; Jeffrey J Cooper; Stanley C Sedore; David H Price
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

10.  P-TEFb- the final frontier.

Authors:  Jiri Kohoutek
Journal:  Cell Div       Date:  2009-09-02       Impact factor: 5.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.